Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 6, 2023

Primary Completion Date

November 8, 2023

Study Completion Date

January 29, 2024

Conditions
Alopecia, Androgenetic
Interventions
DRUG

TDM-105795, 0.0025%

The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

DRUG

TDM-105795, 0.02%

The assigned drug will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

DRUG

TDM-105795 topical vehicle solution

The assigned placebo will be applied once daily for 16 weeks, with application to the scalp focusing on the regions that are bald and thinning.

Trial Locations (13)

23502

Site 2, Norfolk

37130

Site 8, Murfreesboro

37909

Site 5, Knoxville

46168

Site 7, Plainfield

55112

Site 9, New Brighton

55455

Site 10, Minneapolis

60008

Site 4, Rolling Meadows

70115

Site 13, New Orleans

70809

Site 11, Baton Rouge

72116

Site 12, North Little Rock

77845

Site 6, College Station

78759

Site 1, Austin

97210

Site 3, Portland

All Listed Sponsors
collaborator

Therapeutics, Inc.

INDUSTRY

lead

Technoderma Medicines Inc.

INDUSTRY